Vaccine immunotherapy for recurrent brain tumors or newly diagnosed DIPG
Part of Cancer clinical trials.
This trial tests a combination of a vaccine made from tumor cells and a drug that may boost the immune system's ability to fight brain tumors. It is for children and young adults with a recurrent high-grade glioma or a newly diagnosed diffuse midline glioma with a specific genetic marker (H3K27M).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of brain tumor called recurrent high-grade glioma or newly diagnosed DIPG with a specific mutation (H3K27M).
- You have finished radiation at least 14 days ago and are stable on a low dose of steroids for the last 2 weeks.
- You have adequate blood cell counts, liver and kidney function, and a performance score of at least 60%.
- You have not had certain cancer treatments, like targeted therapy or immunotherapy, in the last 28 days.
- You are not pregnant and agree to use effective birth control if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a customized vaccine (made from your tumor’s cell parts) along with an immune “checkpoint blocker” medicine. It’s for newly diagnosed DIPG/DMG to see if this combination is safe and can help control the cancer.
This trial studies a targeted medicine approach for high-grade glioma (a fast-growing brain tumor) and some diffuse midline tumors, including DIPG. It may help by matching treatment to tumor biology using tumor testing done before or around starting standard therapy.
This trial tests a new drug called ADI-PEG 20 combined with standard treatments (temozolomide and radiation) for children and young adults with newly diagnosed high-grade glioma. It aims to see if this combination is safe and effective.
This trial tests a vaccine made from immune cells (dendritic cells) designed to train your body to fight brain tumors like DIPG or glioblastoma. You may qualify if you have one of these tumors, have had standard treatment, and are generally healthy enough for the study.
This trial tests a personalized immune cell therapy for people with a specific type of brain tumor (DIPG or midline glioma) that has the H3K27M mutation. The treatment uses your own immune cells, which are modified to find and attack the tumor.
This trial tests a vaccine that may help the immune system fight brain tumors (medulloblastoma, high-grade glioma, and DIPG). It is for patients who have already had standard treatment and whose tumors are still present or have returned.
Hear when a new Diffuse Midline Glioma, H3 K27M-Mutant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.